Sulfonamide PET Tracers for CA-IX Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PET imaging agents lack specificity and signal-to-background characteristics for cancer diagnosis, particularly for CA-IX expression in tumors, due to non-selective inhibition of CA isoenzymes by sulfonamides and limitations in existing imaging probes.
Innovation Solution
Development of novel sulfonamide compounds with high affinity for CA-IX, designed as PET tracers that selectively inhibit the cancer-related, hypoxia-induced CA-IX isozyme, utilizing a specific chemical structure to achieve cellular impermeability and targeted binding to extracellular CA-IX enzymes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If sulfonamides are used as PET imaging agents, then they can bind to carbonic anhydrase enzymes, but they lack specificity and inhibit multiple CA isoenzymes instead of selectively targeting CA-IX
Solution Approach 1:
The patent applies local quality by introducing a charged moiety at a specific location in the sulfonamide molecule (either as a substituent or as a salt form). This localized modification creates an electrostatic repulsion barrier that prevents cellular uptake while allowing extracellular CA-IX binding, thereby achieving isoenzyme-specific imaging without affecting other intracellular CA isoenzymes.
Solution Approach 2:
The patent changes the physicochemical parameter of the sulfonamide compound by introducing a charged character (either cationic or anionic). This parameter change fundamentally alters the compound's cellular permeability and distribution, enabling selective binding to extracellular CA-IX while preventing entry into cells where other CA isoenzymes are located, thus resolving the specificity issue.
2Measurement precision
If existing PET imaging probes are used, then they can detect tumor metabolism, but they have inadequate signal-to-background characteristics and non-specific uptake
Solution Approach 1:
The charged moiety is strategically positioned in the molecule to create an electrostatic barrier that selectively prevents cellular uptake while maintaining affinity for extracellular CA-IX. This local modification at a critical position enables the probe to accumulate specifically in the extracellular space of tumors where CA-IX is overexpressed, dramatically improving signal-to-background ratio and eliminating non-specific uptake in normal tissues.
Solution Approach 2:
The charged moiety acts as an intermediary element that mediates between the hydrophobic sulfonamide core (which provides CA-binding affinity) and the aqueous extracellular environment. This intermediary charged group creates the necessary electrostatic repulsion to prevent cellular entry while allowing the hydrophobic portion to interact with the extracellular CA-IX enzyme, thereby achieving specific tumor targeting.
3Ease of operation
If cell-permeable tracers are used, then they can enter tumor cells, but they cannot distinguish between intracellular and extracellular CA isoenzymes
Solution Approach 1:
The charged moiety is introduced in advance to create an electrostatic repulsion barrier that actively prevents cellular uptake. This preliminary anti-action against cell membrane penetration ensures that the tracer remains exclusively in the extracellular space, allowing specific targeting of extracellular CA-IX without confounding signals from intracellular CA isoenzymes.
Solution Approach 2:
The patent changes the polarity parameter of the sulfonamide compound by introducing a charged character, which fundamentally alters its membrane permeability properties. This parameter change from neutral to charged state creates an electrostatic barrier that selectively blocks cellular uptake while preserving the compound's ability to bind extracellular CA-IX, thereby achieving spatial specificity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds provide enhanced specificity and sensitivity for CA-IX expression in tumors, enabling accurate diagnostic imaging and monitoring of cancer progression through positron emission tomography, improving the accuracy of cancer diagnosis and treatment monitoring.
Implementation Method 1
designed as PET tracers that selectively inhibit the cancer-related, hypoxia-induced CA-IX isozyme
Implementation Method 2
PET imaging systems create images based on the distribution of positron-emitting isotopes in the tissue of the patient
Implementation Method 3
The compounds of the present application include a charged moiety, either a cation or anion, which prevents cellular uptake of the compounds
Data Source
AI summary
The present application discloses methods for identifying inhibitors with high binding-affinity for the carbonic anhydrase-IX (CA-IX) enzyme using click chemistry and uses the candidates thereof as positron emission tomography (PET) imaging agents.